Viking Therapeutics (VKTX) – Press Releases
-
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
-
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
-
Viking Therapeutics Announces Proposed Public Offering of Common Stock
-
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
-
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023
-
Ligand Reports Third Quarter 2023 Financial Results
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
-
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
-
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
-
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
-
Ligand Reports Second Quarter 2023 Financial Results
-
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
-
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
-
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
-
Ligand Reports First Quarter 2023 Financial Results
-
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023
-
Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
-
Viking Therapeutics Announces Proposed Public Offering of Common Stock
-
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
-
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Present at SVB Securities Global Biopharma Conference
-
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023
-
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
-
Viking Therapeutics to Present at Stifel 2022 Healthcare Conference
-
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022
-
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022
-
Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
-
Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022
-
Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference
-
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Back to VKTX Stock Lookup
